18F-FDG PET/CT评估局部进展期食管胃结合部腺癌新辅助放化疗反应
本前瞻性研究纳入40例可手术局部进展期食管胃结合部腺癌(AEG)患者,在新辅助放化疗前后行18F-FDG PET/CT与增强CT,按PERCIST和RECIST评估反应。基线PET/CT发现6例远处转移而排除手术;ΔSUVmax阈值≤45%与病理反应相关(P=0.033),且与5年无进展生存和总生存相关。
要点
- 基线PET/CT可发现AEG患者未被怀疑的远处转移,6/40例因此排除手术。
- ΔSUVmax≤45%与病理反应相关(P=0.033),并关联5年无进展生存和总生存。
- CT反应与基线SUVmax(P=0.039)及ΔSUVmax(P=0.001)均相关。
核心结论
- 18F-FDG PET/CT有助于在可手术AEG患者新辅助治疗前诊断未被怀疑的转移。
- ΔSUVmax与病理反应相关,且是长期生存的独立预后因素。
研究设计与样本
- 前瞻性研究评估连续入组的可手术局部进展期AEG患者,最终纳入40例。
- 基线及放化疗结束后2周行PET/CT和增强胸腹部CT,分别按PERCIST和RECIST评估反应。
- 手术切除标本采用5级组织病理学评分系统评估回归率;转移灶经病理或影像及6个月临床随访确认。
主要发现
- 病理反应与ΔSUVmax阈值≤45%相关(P=0.033)。
- CT反应与基线SUVmax(P=0.039)及ΔSUVmax(P=0.001)均相关。
- ΔSUVmax阈值≤45%的5年无进展生存和总生存曲线与AEG生存相关。
关键数值与推荐
- PET/CT反应评估采用PERCIST标准,CT反应评估采用RECIST标准。
- 病理反应评估采用手术切除肿瘤的5级组织病理学评分系统。
- ΔSUVmax阈值≤45%用于分析病理反应及5年生存。
临床怎么用
- 对拟行新辅助放化疗的局部进展期AEG患者,基线18F-FDG PET/CT可用于排除未被怀疑的远处转移。
- 治疗前后ΔSUVmax(阈值≤45%)可作为评估病理反应和长期预后的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The outcome of locally advanced adenocarcinoma of the esophagogastric junction (AEG) treated with preoperative chemoradiotherapy is heterogeneous, and favorable response to this treatment is a key factor in the patient's prognosis. The aim of this study was to evaluate F-FDG PET/CT in assessing metabolic response in patients with AEG. MATERIALS AND METHODS: This prospective study evaluated all consecutive patients with potentially operable locally advanced AEG who were candidates for neoadjuvant chemoradiotherapy. PET/CT and contrast-enhanced thoracoabdominal CT were performed at baseline and 2 weeks after completion of chemoradiotherapy for response evaluation. The response rate was assessed using Response Evaluation Criteria in Solid Tumors criteria for contrast-enhanced thoracoabdominal CT and Positron Emission Tomography Response Criteria in Solid Tumors criteria for PET/CT. The regression rate was assessed using a 5-grade histopathology scoring system of the surgically resected tumor. Metastatic lesions were confirmed by histopathology examination or imaging and clinical follow-up at 6 months. RESULTS: A total of 40 cases were finally included in the study. Distant metastases were found in the baseline PET/CT in 6 of 40 cases (retroperitoneal [2] or mediastinal/hiliar [1] lymph nodes and liver [2] or bone [1] metastases) and were therefore excluded from surgery. Pathologic response correlated with the ΛSUVmax threshold of ≤45% (P = 0.033). CT response correlated well with both the baseline SUVmax (P = 0.039) and the ΛSUVmax (P = 0.001). Five-year survival curves for AEG correlated with the ΛSUVmax using a threshold of ≤45% for both progression-free and overall survival. CONCLUSIONS: F-FDG PET/CT is useful for diagnosing nonsuspected metastasis before neoadjuvancy in potentially operable AEG. The ΛSUV correlates with pathologic response and is a long-term independent prognostic factor of survival.
引用
- Sánchez-Izquierdo N, Perlaza P, Pagès M, et al. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma. Clin Nucl Med. 2020. PMID: 31714278. doi:10.1097/RLU.0000000000002840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。